CA2669913C - Endoxifen methods and compositions - Google Patents

Endoxifen methods and compositions Download PDF

Info

Publication number
CA2669913C
CA2669913C CA2669913A CA2669913A CA2669913C CA 2669913 C CA2669913 C CA 2669913C CA 2669913 A CA2669913 A CA 2669913A CA 2669913 A CA2669913 A CA 2669913A CA 2669913 C CA2669913 C CA 2669913C
Authority
CA
Canada
Prior art keywords
endoxifen
acid
use according
composition
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2669913A
Other languages
English (en)
French (fr)
Other versions
CA2669913A1 (en
Inventor
Ateeq Ahmad
Shoukath M. Ali
Moghis U. Ahmad
Saifuddin Sheikh
Imran Ahmad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jina Pharmaceuticals Inc
Original Assignee
Jina Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2669913(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jina Pharmaceuticals Inc filed Critical Jina Pharmaceuticals Inc
Publication of CA2669913A1 publication Critical patent/CA2669913A1/en
Application granted granted Critical
Publication of CA2669913C publication Critical patent/CA2669913C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2669913A 2006-11-21 2007-11-21 Endoxifen methods and compositions Active CA2669913C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86042006P 2006-11-21 2006-11-21
US60/860,420 2006-11-21
US86078806P 2006-11-22 2006-11-22
US60/860,788 2006-11-22
PCT/US2007/085443 WO2008070463A2 (en) 2006-11-21 2007-11-21 Endoxifen methods and compositions

Publications (2)

Publication Number Publication Date
CA2669913A1 CA2669913A1 (en) 2008-06-12
CA2669913C true CA2669913C (en) 2012-09-18

Family

ID=39492975

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2669913A Active CA2669913C (en) 2006-11-21 2007-11-21 Endoxifen methods and compositions

Country Status (11)

Country Link
US (2) US9333190B2 (enExample)
EP (1) EP2101731B1 (enExample)
JP (1) JP2010510327A (enExample)
CA (1) CA2669913C (enExample)
DK (1) DK2101731T3 (enExample)
ES (1) ES2665917T3 (enExample)
HU (1) HUE037109T2 (enExample)
IN (1) IN2014MN00139A (enExample)
PL (1) PL2101731T3 (enExample)
PT (1) PT2101731T (enExample)
WO (1) WO2008070463A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
ES2624557T3 (es) * 2008-12-11 2017-07-14 Besins Healthcare Luxembourg Sarl Composiciones farmacéuticas transdérmicas que comprenden un SERM
SI3228319T1 (sl) 2011-04-28 2020-10-30 Oncopeptides Ab Liofiliziran pripravek citotoksičnih dipeptidov
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
JP6284945B2 (ja) * 2012-10-26 2018-02-28 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ メルファランフルフェナミドの凍結乾燥製剤
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
DE102015222031A1 (de) 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
US20170304232A1 (en) * 2016-04-20 2017-10-26 Northwestern University Endoxifen For Local Transdermal Therapy To The Breast
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
AU2021252229A1 (en) 2020-04-10 2022-10-27 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar I disorder
CA3185993A1 (en) 2020-04-10 2021-10-14 Jina Pharmaceuticals, Inc. Endoxifen for the treatment of bipolar i disorder
US20220296514A1 (en) * 2021-03-18 2022-09-22 FormuRx Pharmaceuticals Co., Ltd. Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids
IL314075A (en) 2022-01-12 2024-09-01 Atossa Therapeutics Inc Compositions of (Z)-endoxifen and methods for their enrichment
EP4514327A1 (en) * 2022-04-26 2025-03-05 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ATE252373T1 (de) * 1994-08-04 2003-11-15 Elan Drug Delivery Ltd Feste verabreichungssysteme zur gesteuerten freisetzung von darin eingebauten molekülen sowie verfahren zu deren herstellung
AU736301B2 (en) * 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
WO2008048194A1 (en) 2006-10-20 2008-04-24 Yesilogluj Aysegul Yildiz Use of the protein kinase c inhibitor tamoxifen for the treatment of bipolar disorder
US9637515B2 (en) 2006-11-06 2017-05-02 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
PT2101731T (pt) 2006-11-21 2018-04-18 Jina Pharmaceuticals Inc Endoxifeno para utilização no tratamento de cancro
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
JP5720881B2 (ja) 2011-01-31 2015-05-20 東芝ライテック株式会社 Ｌｅｄランプ点灯装置および照明装置

Also Published As

Publication number Publication date
EP2101731A4 (en) 2011-04-20
US9333190B2 (en) 2016-05-10
EP2101731A2 (en) 2009-09-23
WO2008070463A9 (en) 2008-09-18
WO2008070463A3 (en) 2008-11-06
ES2665917T3 (es) 2018-04-30
CA2669913A1 (en) 2008-06-12
PT2101731T (pt) 2018-04-18
US10376479B2 (en) 2019-08-13
WO2008070463A2 (en) 2008-06-12
US20100112041A1 (en) 2010-05-06
US20160346230A1 (en) 2016-12-01
IN2014MN00139A (enExample) 2015-06-19
EP2101731B1 (en) 2018-01-31
DK2101731T3 (en) 2018-04-16
PL2101731T3 (pl) 2018-07-31
JP2010510327A (ja) 2010-04-02
HUE037109T2 (hu) 2018-08-28

Similar Documents

Publication Publication Date Title
US11672758B2 (en) Endoxifen methods and compositions for inhibition of protein kinase C
US10376479B2 (en) Endoxifen compositions and methods
US20120164075A1 (en) Endoxifen methods and compositions in the treatment of mammalian diseases
EP1673063B1 (en) Transdermal pharmaceutical composition
CN106924176B (zh) 一种他莫昔芬柔性纳米脂质体凝胶剂及其制备方法
JP5069131B2 (ja) 動物へのｎｄｇａ化合物を包含するカテコールブタンの注射のための製剤
CN102159202A (zh) 施用局部抗真菌制剂治疗真菌感染的方法
WO2015117136A1 (en) Boronic acid esters and pharmaceutical formulations thereof
CN104703594A (zh) 稳定的封装奥沙利铂的脂质体的水分散体及其稳定化方法
CN104706597B (zh) 一种用于鼻腔给药的尼莫地平脂质体及其制备方法
RU2389483C2 (ru) Химически устойчивые композиции 4-гидрокси-тамоксифена
WO2022003443A1 (ko) 양이온성 리포좀을 포함하는 사포닌의 용혈 억제용 조성물
HK1136198A (en) Endoxifen for use in the treatment of cancer
HK1136198B (en) Endoxifen for use in the treatment of cancer
WO2017107895A1 (zh) 口服制剂及其制备方法
CN101150956B (zh) 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
TW202448515A (zh) 汰癌勝結合物化合物、組成物、及其等的使用方法
JP2007535505A (ja) ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241115

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251114

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251114